NEW YORK, June 28, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ImmunoCellular Therapeutics, Ltd. from May 1, 2012 through December 11, 2013, inclusive (the "Class Period") of the important June 30, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for ImmunoCellular investors under the federal securities laws.
To join the ImmunoCellular class action, go to http://rosenlegal.com/cases-1115.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well. As a result of this scheme, ImmunoCellular's share price was artificially inflated. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1115.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imuc-alert-rosen-law-firm-reminds-immunocellular-therapeutics-ltd-investors-of-important-june-30-deadline-in-class-action--imuc-300481420.html
SOURCE Rosen Law Firm, P.A.